Article tools
Author information
Published in Volume 100, Issue 6 (September 15,1997)
J. Clin. Invest. 100(6): 1344-1348 (1997). doi:10.1172/JCI119654.
Copyright © 1997, The American Society for Clinical Investigation

Research Article

Metabolically inactive insulin analog prevents type I diabetes in prediabetic NOD mice.

D G Karounos, J S Bryson and D A Cohen

Department of Internal Medicine, Veterans Administration Medical Center and University of Kentucky College of Medicine, Lexington, Kentucky 40536-0084, USA. dkaroun@pop.uky.edu

Published September 15, 1997

The purpose of this study was to determine the relative importance of the metabolic effects of insulin for diabetes prevention by administering insulin or an inactive insulin analog by daily subcutaneous injections to prediabetic mice. A recombinant monomeric human insulin analog, which does not bind to the insulin receptor as a consequence of an alteration of a single amino acid at position 25 of the B chain, was shown to be equally effective at diabetes prevention as was intact insulin. In contrast to native insulin, the insulin analog did not cause hypoglycemia after subcutaneous injection. The insulin analog, however, protected young adult mice from diabetes, even when it was initiated after the onset of extensive lymphocytic infiltration of the islets. Thus, preventative therapy by daily subcutaneous injections of insulin does not require the hypoglycemic response, or binding to the insulin receptor to prevent the onset of type I diabetes.

This article Copyright © 1997, The American Society for Clinical Investigation.

Articles that cite this article:

TOLERANCE TO ISLET AUTOANTIGENS IN TYPE 1 DIABETES
Jean-Francois Bach, Lucienne Chatenoud
annu rev immunol 19(1):131. doi:10.1146/annurev.immunol.19.1.131 [CrossRef]

Effects of insulin administration in a group of high-risk, non-diabetic, first-degree relatives of Type 1 diabetic patients: an open pilot trial
C. Rodriguez-villar, I. Conget, R. Casamitjana, G. Ercilla, R. Gomis
Diabetic Med 16(2):160. doi:10.1046/j.1464-5491.1999.00044.x [CrossRef]

Transgenes and knockout mutations in animal models of type 1 diabetes and multiple sclerosis
F. Susan Wong, Bonnie N. Dittel, Charles A. Janeway
Immunol Rev 169(1):93. doi:10.1111/j.1600-065X.1999.tb01309.x [CrossRef]

Inhaled Insulin and Insulin Antibodies: A New Twist to an Old Debate
James A. Stoever, Jerry P. Palmer
diabetes technol ther 4(2):157. doi:10.1089/15209150260007372 [CrossRef]

The molecular specificity of insulin autoantibodies
Kathleen N. Potter, Terence J. Wilkin
Diabetes Metab Res Rev 16(5):338. doi:10.1002/1520-7560(2000)9999:9999<::AID-DMRR145>3.0.CO;2-L [CrossRef]

Preservation of C-peptide secretion in subjects at high risk of developing type 1 diabetes mellitus - a new surrogate measure of non-progression?
Desmond Schatz, David Cuthbertson, Mark Atkinson, Michael Clare Salzler, William Winter, Andrew Muir, Janet Silverstein, Roberta Cook, Noel Maclaren, Jin-Xiong She
Pediatr Diabetes 5(2):72. doi:10.1111/j.1399-543X.2004.00047.x [CrossRef]

Animal models of diabetes mellitus
D. A. Rees, J. C. Alcolado
Diabetic Med 22(4):359. doi:10.1111/j.1464-5491.2005.01499.x [CrossRef]

CD3-specific antibodies: a portal to the treatment of autoimmunity
Lucienne Chatenoud, Jeffrey A. Bluestone
Nat Rev Immunol 7(8):622. doi:10.1038/nri2134 [CrossRef]

New therapeutic approaches to type 1 diabetes: from prevention to cellular or gene therapies
Charles Thivolet
Clin Endocrinol (Oxf) 55(5):565. doi:10.1046/j.1365-2265.2001.01398.x [CrossRef]